# EDGAR Filing Document

**Accession Number:** 0001091596
**File Stem:** 0001437749-23-008848
**Filing Date:** 2023-3
**Character Count:** 6826
**Document Hash:** 6088f61b98e490626132ffa796958c65
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-23-008848.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0001437749-23-008848

**CONFORMED SUBMISSION TYPE**: NT 10-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230331

**DATE AS OF CHANGE**: 20230331

**EFFECTIVENESS DATE**: 20230331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nuo Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001091596
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 233011702
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NT 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32518
- **FILM NUMBER:** 23788245

**BUSINESS ADDRESS:**
- **STREET 1:** 8285 EL RIO, SUITE 150
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77054
- **BUSINESS PHONE:** 832-236-9060

**MAIL ADDRESS:**
- **STREET 1:** 8285 EL RIO, SUITE 150
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77054

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Nuo Therapeutics, Inc
- **DATE OF NAME CHANGE:** 20141112

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CYTOMEDIX INC
- **DATE OF NAME CHANGE:** 20000511

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AUTOLOGOUS WOUND THERAPY INC
- **DATE OF NAME CHANGE:** 20000407

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

SEC File Number: 000-28443

CUSIP Number: 67059V209

☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR

For Period Ended: <u>December 31, 2022</u>

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

☐ Transition Report on Form N-SAR

For the Transition Period Ended: _____________

**Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.**

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I - REGISTRANT INFORMATION**

---

| |
|:---|
| **Nuo Therapeutics, Inc.** |
| Full Name of Registrant |

---

---

| |
|:---|
| **Not Applicable** |
| Former Name if Applicable |

---

---

| |
|:---|
| **8285 El Rio, Suite 190** |
| Address of Principal Executive Office |

---

---

| |
|:---|
| **Houston, TX 77054** |
| City, State and Zip Code |

---

**PART II - RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp;&nbsp;&nbsp;(a) | The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
| ☒ | &nbsp;&nbsp;&nbsp;&nbsp;(b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
|  | &nbsp;&nbsp;&nbsp;&nbsp;(c) | The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |

---

------

**PART III - NARRATIVE**

Nuo Therapeutics, Inc. (the "Registrant") is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the "Form 10-K") within the prescribed time-period because the Registrant is awaiting final review of its financial statements by its independent registered public accounting firm. In contrast to the Registrant's preceding comprehensive annual report covering three fiscal years of 2019, 2020, and 2021, the Form 10-K will cover two fiscal years including 2022 when the Registrant reestablished commercial operations. As a result, additional effort and expense has been required to complete the 2022 year-end reporting processes and related audit procedures. The Registrant expects to continue to report substantial doubt exists about its ability to continue as a going concern. The Registrant currently intends to file the Form 10-K within the 15-calendar day extension provided by Rule 12b-25.

*Forward-Looking Statements* 

This Form 12b-25 contains forward-looking statements, which are based on management's current expectations or beliefs about the Registrant's future plans, expectations, and objectives. These forward-looking statements are not historical facts and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by these forward-looking statements including, including statements regarding the Registrant's intention to file the Form 10-K and on or before the fifteenth calendar day following the prescribed due date for filing the Form 10-K. Readers of this Form 12b-25 are cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date of this Form 12b-25.

**PART IV - OTHER INFORMATION**

(1) Name and telephone number of person to contact in regard to this notification

---

| | | |
|:---|:---|:---|
| **David E. Jorden** | **346** | **396-4770** |
| (Name) | (Area Code) | (Telephone Number) |

---

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☐ No ☒

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

------

---

| |
|:---|
| **Nuo Therapeutics, Inc.** |
| (Name of Registrant as Specified in Charter) |

---

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: March 31, 2023 | By: | /s/ David E. Jorden |
|  |  | David E. Jorden |
|  |  | *Chief Executive Officer &*<br> *Chief Financial Officer* |

---